Literature DB >> 18469794

Tumor infiltrating lymphocytes differ in invasive micropapillary carcinoma and medullary carcinoma of breast.

Xiaojing Guo1, Yu Fan, Ronggang Lang, Feng Gu, Ling Chen, Lifang Cui, Gordon A Pringle, Xinmin Zhang, Li Fu.   

Abstract

Tumor infiltrating lymphocytes have been correlated with a better prognosis for some tumors and medullary carcinoma of breast is a good example. However, in a recent study of invasive micropapillary carcinoma of breast, tumor infiltrating lymphocytes were associated with increased lymph node metastasis and a poorer prognosis. To explore possible mechanisms underlying this difference in immune responsiveness and tumor behavior, 28 cases of invasive micropapillary carcinoma with prominent lymphocyte infiltration were compared with 29 cases of medullary carcinoma. In both tumors, the majority of tumor infiltrating lymphocytes were T lymphocytes (P<0.01) with CD8+ T lymphocytes predominant (P<0.01). Significantly, functional differences in CD8+ cytotoxic T lymphocytes were identified in the two types of tumor. While lymphocytes infiltrated both the stroma and epithelial components of medullary carcinoma, the tumor infiltrating lymphocytes of invasive micropapillary carcinoma were almost exclusively confined to the stroma. Tumor infiltrating lymphocytes of medullary carcinoma showed stronger expression of FasL than those in invasive micropapillary carcinoma (P<0.01) and medullary carcinoma cells exhibited stronger expression of Fas than invasive micropapillary carcinoma cells did (P<0.01). In the subgroups of tumors with strong (++/+++) Fas expression, double immunohistochemistry revealed that most of the tumor infiltrating lymphocytes in medullary carcinoma, particularly those infiltrating the tumor nests, were CD8+ cytotoxic T lymphocytes, but not so in invasive micropapillary carcinoma. Furthermore, upregulated expression of perforin, granzyme B and FasL by cytotoxic T lymphocytes was greater in medullary carcinoma than invasive micropapillary carcinoma (P<0.01, respectively). The results suggest that effective immunity provided by tumor infiltrating lymphocytes varies in different tumors and the relative lack of tumor-killing cytotoxic T lymphocytes in invasive micropapillary carcinoma may explain, in part, the adverse association of tumor infiltrating lymphocytes with the biological behavior of invasive micropapillary carcinoma of breast.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18469794     DOI: 10.1038/modpathol.2008.72

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  15 in total

1.  A comprehensive information database (CID) of breast cancer patients in China.

Authors:  Shuai Li; Li Fu
Journal:  Front Med       Date:  2012-05-08       Impact factor: 4.592

2.  A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE.

Authors:  Jian Zhang; Huizhong Li; Dazhi Gao; Baofu Zhang; Maojin Zheng; Mingyin Lun; Mengxue Wei; Rui Duan; Maomao Guo; Jiajun Hua; Qian Liu; Jin Bai; Hui Liu; Junnian Zheng; Hong Yao
Journal:  Cancer Biol Ther       Date:  2018-03-06       Impact factor: 4.742

3.  Micropapillary component in gastric adenocarcinoma: an aggressive variant associated with poor prognosis.

Authors:  Qingfu Zhang; Jian Ming; Siyang Zhang; Bo Li; Liying Yin; Xueshan Qiu
Journal:  Gastric Cancer       Date:  2014-02-22       Impact factor: 7.370

4.  Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

Authors:  Edith A Perez; E Aubrey Thompson; Karla V Ballman; S Keith Anderson; Yan W Asmann; Krishna R Kalari; Jeanette E Eckel-Passow; Amylou C Dueck; Kathleen S Tenner; Jin Jen; Jian-Bing Fan; Xochiquetzal J Geiger; Ann E McCullough; Beiyun Chen; Robert B Jenkins; George W Sledge; Eric P Winer; Julie R Gralow; Monica M Reinholz
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

Review 5.  Dissecting the Potential Interplay of DEK Functions in Inflammation and Cancer.

Authors:  Nicholas A Pease; Trisha Wise-Draper; Lisa Privette Vinnedge
Journal:  J Oncol       Date:  2015-09-06       Impact factor: 4.375

6.  The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.

Authors:  Michael J Campbell; Denise Wolf; Rita A Mukhtar; Vickram Tandon; Christina Yau; Alfred Au; Frederick Baehner; Laura van't Veer; Donald Berry; Laura J Esserman
Journal:  PLoS One       Date:  2013-10-29       Impact factor: 3.240

7.  CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.

Authors:  Ankita Singh Rathore; Sandeep Kumar; Rituraj Konwar; Annu Makker; M P S Negi; Madhu Mati Goel
Journal:  Indian J Med Res       Date:  2014-09       Impact factor: 2.375

8.  Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.

Authors:  Gerardo Botti; Francesca Collina; Giosuè Scognamiglio; Federica Rao; Valentina Peluso; Rossella De Cecio; Michela Piezzo; Gabriella Landi; Michelino De Laurentiis; Monica Cantile; Maurizio Di Bonito
Journal:  Int J Mol Sci       Date:  2017-02-21       Impact factor: 5.923

9.  Immunohistochemical analysis of medullary breast carcinoma autoantigens in different histological types of breast carcinomas.

Authors:  Olga Kostianets; Stepan Antoniuk; Valeriy Filonenko; Ramziya Kiyamova
Journal:  Diagn Pathol       Date:  2012-11-26       Impact factor: 2.644

10.  Osteosarcoma microenvironment: whole-slide imaging and optimized antigen detection overcome major limitations in immunohistochemical quantification.

Authors:  Pierre Kunz; Jörg Fellenberg; Linda Moskovszky; Zoltan Sápi; Tibor Krenacs; Johannes Poeschl; Burkhard Lehner; Miklos Szendrõi; Volker Ewerbeck; Ralf Kinscherf; Benedikt Fritzsching
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.